文献

PA007393.m1: Syd Labs体内实验级重组抗人CD64单克隆抗体（克隆号M22），小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD64 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: M22)）

抗人CD64单抗（M22）部分引用文献:

1. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy.
Izumi, et al. Front Immunol. 2021 Mar 5;12:618081. PMID: 33746979
“As hematopoietic progenitors supply a large number of blood cells, therapeutic strategies targeting them are potentially beneficial to eliminate unwanted leukemic cells. …Here, we introduce a dimeric pyrrolobenzodiazepine (dPBD)-conjugated anti-CD64 antibody that selectively induces the apoptosis of proliferating human monocyte-restricted progenitors. …Given the selective action on proliferating monocyte progenitors, it should be a promising tool to target cancers and inflammatory disorders with minimal side effects.”

2. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody: A potential strategy to enhance anti-TNF therapy.
Hristodorov, et al. mAbs. 2014;6(5):1283-1289. PMID: 25517313
“Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that plays a critical role in inflammatory diseases, typically neutralized by therapeutic monoclonal antibodies. …However, therapeutic anti-TNF mAbs can be captured by the high-affinity IgG receptor FcγRI (CD64) expressed on activated macrophages, reducing their availability and efficacy. …In this study, we demonstrate that a single-chain antibody fragment specifically binds to CD64, preventing the capture of anti-TNF mAbs and potentially enhancing therapies.”

3. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov, et al. Oncotarget. 2016 Oct 25;7(43):70295-70305. PMID: 27564103
“Fc gamma receptor I (FcγRI, CD64) is a well-known target antigen for passive immunotherapy against acute myeloid leukemia and chronic myelomonocytic leukemia. …We recently reported the preclinical immunotherapeutic potential of microtubule associated protein tau (MAP) against a variety of cancer types including breast carcinoma and Hodgkin’s lymphoma. …Here we demonstrate that a CD64-directed human cytolytic fusion protein selectively kills CD64-positive leukemic blasts ex vivo, highlighting its potential for treating CD64-positive leukemias.”

4. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation.
Heo, et al. J Control Release. 2017 Jan 28;246:125-134. PMID: 28003138
“Monocytes and macrophages play key roles in various inflammatory diseases, making them highly attractive targets for RNA interference (RNAi) therapeutics. …To achieve targeted siRNA delivery, we developed a liposomal formulation surface-modified with a human CD64-specific single-chain antibody. …Our results indicate that this human CD64-targeted delivery system efficiently promotes specific cellular uptake of siRNA and gene silencing in human primary monocytes.”

5. Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia.
Kopertekh, et al. Front Plant Sci. 2023 Aug 9;14:1229490. PMID: 37637255
“Monocytic leukemia is a severe hematological malignancy that requires novel targeted therapies to overcome drug resistance and improve patient outcomes. …We designed and optimized a set of recombinant immunotoxins targeting the human CD64 receptor, utilizing transient expression in plant systems for rapid production. …Activity testing of these plant-derived immunotoxins demonstrated robust and specific cytotoxicity against CD64-expressing leukemic cells, validating this platform for biopharmaceutical development.”